⚡ The Short Answer
Section 503A of the Federal Food, Drug, and Cosmetic Act allows traditional compounding pharmacies to prepare medications for individual patients based on valid prescriptions. In 2026, this is the primary legal pathway for compounded semaglutide and tirzepatide — but only when a prescriber documents a clinical need that differentiates the compounded product from the commercially available version.
The key requirement: each prescription must be patient-specific with documented medical necessity. Mass production under 503A is not permitted.
503A vs. 503B: Understanding the Difference
Federal law creates two distinct pathways for compounding medications. Understanding the difference matters because it determines the level of oversight, the scale of production, and — as of 2026 — which pathway is still available for GLP-1 medications.
| Feature | 503A Pharmacy | 503B Outsourcing Facility |
|---|---|---|
| Primary Regulator | State Pharmacy Board | FDA (federal) |
| Quality Standard | USP <797> Guidelines | cGMP Manufacturing |
| Batch Testing | Sample-based (periodic) | Every batch, mandatory |
| Production Scale | Patient-specific (Rx only) | Bulk / office use |
| Prescription Required? | Yes, always | Not always (office use) |
| GLP-1 Status (2026) | Available with conditions | Not available |
During the semaglutide and tirzepatide shortages (2022–2024), both 503A and 503B facilities could compound these drugs under the shortage exemption. That exemption ended when the FDA declared the shortages resolved: tirzepatide in October 2024 (503B enforcement by March 19, 2025) and semaglutide in February 2025 (503A enforcement April 22, 2025; 503B enforcement May 22, 2025).
The result: 503B outsourcing facilities can no longer produce semaglutide or tirzepatide at scale. Only 503A pharmacies, operating under the traditional patient-specific compounding exemption, retain a legal pathway — and even that requires meeting specific conditions.
What Makes 503A Compounding Legal in 2026
Section 503A doesn’t give pharmacies a blank check to compound anything. To legally prepare semaglutide or tirzepatide, a 503A pharmacy must meet all of these requirements simultaneously:
The 503A Checklist for GLP-1 Compounding
Valid patient-specific prescription
A licensed prescriber must write a prescription for an individual patient. “Anticipatory” or bulk compounding without identified patients is not permitted.
Documented clinical differentiation
The prescriber must document why the compounded version is medically necessary — a different dose, an added ingredient (like B12 for nausea), an allergy to an inactive ingredient in the brand product, or another clinical justification. “It’s cheaper” is not sufficient.
Not an “essentially a copy”
The compounded product cannot be essentially a copy of a commercially available drug. This is where the B12 or niacinamide additions become legally significant — they create a “clinically meaningful difference” from the brand product.
Licensed pharmacy with state board oversight
The compounding pharmacy must hold valid state licensure in every state where it ships. Multi-state compounding requires multi-state licensing.
FDA-registered API source using base form
The bulk drug substance must come from an FDA-registered facility and should be semaglutide base (not sodium or acetate salt forms).
The “Personalization” Requirement in Practice
The most significant post-shortage change for patients is the personalization requirement. During the shortage, compounding pharmacies could prepare semaglutide at standard doses (0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg) that were essentially identical to Wegovy. That’s no longer sufficient.
In 2026, legitimate 503A compounded semaglutide programs typically include one or more of these clinical differentiators:
Added vitamins or supplements: B12 (cyanocobalamin), B6 (pyridoxine), or niacinamide added to the formulation. The B12 addition is the most common approach — it creates a genuinely different product from Wegovy while also providing a potential benefit (B12 deficiency is a known concern with GLP-1 medications).
Non-standard dosing: Doses that aren’t available in the commercial product (e.g., 0.375mg, 0.75mg, 1.25mg). This allows more granular titration than the fixed-dose Wegovy pen system permits.
Alternative delivery formats: Some providers offer sublingual troches or drops, though bioavailability concerns with these formats are well-documented. Injectable formulations from multi-dose vials remain the most clinically proven delivery method.
The FDA has flagged “sham personalization” as an enforcement target. If a provider prescribes the same formulation to every patient with no genuine clinical reasoning, that’s not personalization — it’s mass production with a fig leaf. Novo Nordisk has cited this specifically in their federal lawsuits against compounders.
Quality Considerations Under 503A
One honest assessment patients should understand: 503A pharmacies operate under less stringent quality requirements than 503B outsourcing facilities or brand-name drug manufacturers. This doesn’t mean they’re unsafe, but it means the burden shifts to patients to verify quality.
Key quality markers to look for in a 503A pharmacy:
PCAB Accreditation: Pharmacy Compounding Accreditation Board certification (now administered by ACHC) indicates voluntary adherence to higher quality standards. Not required, but a strong positive indicator.
Sterility testing: Ask about their sterility testing schedule. 503A pharmacies aren’t required to test every batch, but reputable ones maintain regular testing programs.
Potency testing: The FDA found 42–170% potency variation in compounded semaglutide products. Ask whether your pharmacy conducts potency testing and whether they can provide results for your lot.
Cold-chain shipping: Semaglutide requires temperature-controlled shipping. Validated packaging with ice packs and temperature monitoring is the standard you should expect.
Compare Providers Using 503A Pharmacies
See which providers source from accredited 503A compounding pharmacies with documented quality programs.
Compare Verified Providers →What Could Change
The 503A pathway for GLP-1 compounding remains legally available but under significant pressure. Several developments could narrow or expand access:
Further FDA enforcement: The February 2026 enforcement announcement from Commissioner Makary and the 30+ warning letters issued in March 2026 signal continued aggressive oversight. Providers that don’t genuinely meet the personalization and clinical differentiation requirements face increased scrutiny.
Court rulings: Ongoing litigation between the Outsourcing Facilities Association (OFA) and the FDA, plus Novo Nordisk’s 132 federal lawsuits, could produce rulings that either strengthen or weaken the 503A pathway for these specific drugs.
New drug approvals: The expected FDA approval of orforglipron (PDUFA date April 10, 2026) could reshape the market by introducing a cheaper oral GLP-1 option that reduces demand for compounded products altogether.
For now, 503A remains the legal framework that sustains legitimate compounded GLP-1 access. Patients who understand how it works are better positioned to evaluate their providers and protect their health.
GLP-1 Compound Pharmacy Editorial Team
Independent research and analysis of the compounded GLP-1 market. We track FDA enforcement, verify provider credentials, and report the facts patients need to make informed decisions.